Research Article
Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia
Table 5
Factors associated with optimal dosing of ACEIs (n=230).
| | Variables | ACEIs dose | COR (95% CI) | p-value | AOR (95%CI) | p-value | | Optimal, n (%) | Suboptimal, n (%) |
| | Age category | | | | | | |
| | <65 | 69 (84.1) | 97 (65.5) | 1 | 1 | 1 | 1 |
| | ≥65 | 13 (15.9) | 51 (34.5) | 2.79 (1.41-5.52) | 0.003 | 2.61 (1.20-5.64) | 0.015 |
| | Hospitalization in the last one year | | | | | | |
| | No | 48 (58.5) | 46 (31.1) | 1 | 1 | 1 | 1 |
| | Yes | 34 (41.5) | 102 (68.9) | 3.13 (1.79-5.48) | P<0.001 | 2.08 (1.11-3.92) | 0.024 |
| | NYHA class | | | | | | |
| | I | 10 (12.2) | 11 (7.4) | 1 | 1 | 1 | 1 |
| | II | 48 (58.5) | 77 (52) | 1.51 (0.58-3.92) | 0.40 | 1.70 (0.54-4.87) | 0.395 |
| | III | 24 (29.3) | 60 (40.5) | 2.59 (0.97-6.93) | 0.057 | 2.27 (0.72-7.19) | 0.163 |
| | Number of comorbidities | | | | | | |
| | <2 | 40 (48.8) | 39 (26.4) | 1 | 1 | 1 | 1 |
| | >=2 | 42 (51.2) | 109 (73.6) | 2.90 (1.64-5.11) | P<0.001 | 1.85 (0.96-3.60) | 0.068 |
| | Valvular heart disease | | | | | . | |
| | No | 67 (81.7) | 132 (89.2) | 1 | 1 | 1 | 1 |
| | Yes | 15 (18.3) | 16 (10.8 | 0.50 (0.23-1.09) | 0.082 | 0.54 (0.22-1.33) | 0.180 |
| | Diuretic use | | | | | | |
| | No | 37 (45.1) | | 1 | 1 | 1 | 1 |
| | Yes | 45 (54.9) | | 5.94 (3.08-11.46) | P<0.001 | 5.60 (2.75-11.40) | P<0.001 |
| | Dose of furosemide | | | | | | |
| | ≤40 mg | 40 (89) | 79 (60.8) | | | | |
| | >40 mg | 5 (11) | 51 (39.2) | 5.17 (1.91-14.0) | 0.001 | 9.80 (3.00-31.98) | P<0.001 |
|
|
NYHA, New York Heart Association, ACEIs, angiotensin converting enzyme inhibitors, COR, crude odds ratio, AOR, adjusted odds ratio, and CI, confidence interval.
|
